As the UK aesthetics sector continues to evolve, polynucleotides have emerged as one of the most talked about additions to the injectable treatment landscape. These regenerative compounds, designed to stimulate skin repair and rejuvenation, are rapidly gaining traction among both providers and patients across the UK.

Our latest market snapshot, produced using the Rare: Monitor dataset and supported by consumer insights gathered in partnership with our friends at Rejuvorate, identifies five defining characteristics of the UK polynucleotides market. For providers, manufacturers and investors, these insights offer a clear view of where the opportunity lies, and what may be required to act on it.

1. There is currently high market growth

As of March 2025, there are around 3,000 providers across the UK were actively offering polynucleotide treatments, and we have seen this growth double over the last 12 months with manufacturers and distributors such as Dermafocus, Fox Pharma and Church Pharmacy taking the discussion to the market. Despite the recent successes, it remains to be seen how muchthese products will be able to penetrate the UK market.

For investors, this suggests a compelling early-stage opportunity: the market is expanding quickly, but remains highly fragmented and largely unconsolidated. For manufacturers, there is still space to become the defining player in what could soon become a core injectable category.

2. Increased consumer spend.

Patients receiving polynucleotides often require multiple injection sessions as part of the treatment protocol, which also provides a higher consumer spend as a result. More than 25% of consumers who received polynucleotide injectables in the past year had treatment three or more times, and spend levels are on average 8% higher than other facial injectable treatments.

This pattern of repeat behaviour suggests that polynucleotides lend themselves well to treatment planning, course-based protocols, and premium positioning. For clinics and providers, this translates into improved customer retention and higher average annual revenue per patient. It also presents an opportunity for manufacturers to support their partners with structured, outcome-driven product positioning.

Overview of consumers having polynucleotide treatment.
Source: Rare:

3. Aligned with Existing Injectable Treatment Ecosystems

A key feature of polynucleotide adoption in the UK is its integration into existing treatment repertoires. According to Rare: Monitor data, 98% of providers offering polynucleotides also provide botulinum toxin, and 97% offer dermal fillers. Many also offer skin boosters, bio-stimulators and other regenerative therapies.

This close alignment suggests that polynucleotides are not viewed as standalone or fringe options, but as complementary, and potentially a valuable addition to clinics already specialising in injectables. This lowers the barrier to adoption and offers manufacturers an opportunity to engage providers through portfolio-based strategies and training support.

4. Geographic and Socioeconomic Concentration

The distribution of providers offering polynucleotides reveals a clear pattern: 86% are located in urban areas, and 47% operate in regions with high household income. Unsurprisingly, Greater London dominates in terms of volume, accounting for 23% of all providers. However, indexed demand is also notably high in regions such as Northern Ireland, South East England, and Yorkshire and the Humber.

For investors and operators, this highlights two key commercial routes: continued growth in already-established urban centres, and early expansion into emerging high-index regions where supply is currently limited.

Distribution of polynucleotides providers in the UK
Source: Rare: Monitor

5. A Fragmented Market with Significant Upside

Perhaps most significantly, only 5% of all polynucleotides treatments in the UK are delivered by the top ten providers. This underscores how fragmented the market remains — and how much opportunity exists for consolidation, brand establishment, or network-driven growth.

Whether through acquisition, franchise models, or national distribution strategies, there is a clear pathway for organisations looking to build scale and market leadership.

The polynucleotides market in the UK is showing all the hallmarks of an emerging category with long-term potential.

For manufacturers, this is a critical time to establish brand authority and build strategic clinic partnerships. For providers, polynucleotides represent a commercially viable, clinically credible treatment with strong retention. And for investors, the fragmented nature of the market, combined with clear demand, makes for a uniquely timed growth opportunity.

Download more free reports from Rare: